There has been an increased frequency of cervical intraepithelial neoplasia (CIN) in pregnancy. The incidence of invasive cervical cancer in pregnancy is between 1.6 to 10.6 per 10,000 pregnancies. The incidence of abnormal cytologic findings during pregnancy is 0.72–1.67%. If the experienced colposcopist estimates that the lesion is intraepithelial, biopsy can be omitted, because the finding of preinvasive disease does not influence the decision on therapy during pregnancy. Biopsy is thus limited to highly significant lesion, where invasion cannot be otherwise excluded. Endocervical curettage (ECC) should be avoided during pregnancy. The natural history of CIN in pregnancy explains why no treatment of these lesions in pregnancy is necessary. The rate of progression to invasive cervical cancer is longer than the gestation. The treatment of Invasive Cervical Cancer should be planned in collaboration with an Oncologist. It is possible currently to give chemotherapy to delay delivery by a few weeks to get a viable foetus. Prognosis of pregnant patients with cervical cancer is the same as that of non pregnant patients.